Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Pharmaceutic, chemical company Monsanto was found liable by a Washington jury for $100 million on Tuesday, according to ...

Bayer (BAYGn.DE), opens new tab will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in ...

Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone, and elinzanetant.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

2025 Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview ...

Bayer's expanded therapies and strategic collaborations in India aim to drive pharmaceutical growth amidst regulatory challenges and pricing pressures.

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...